Recombinant Anti-TG x Anti-TPO Bispecific Antibody (scFv-CH1/CL) is designed to be expressed as two chains. One scFv from an anti-TG antibody variable domain is fused to CH1 and the other scFv from an anti-TPO antibody variable domain fused to CL, or vice versa. And the CH1 and CL domains are linked covalently via a natural disulfide bond. This BsAb can bind two antigens simultaneously and block the synthesis of thyroid hormones. It is designed for the research of Autoimmune thyroid disease therapy.